Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 5 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Imbria Pharmaceuticals Inc. has 9 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 9 examiners across 5 art units, showing a broad examiner spread across a more limited set of technical units. Prosecution management should therefore distinguish common art-unit issues from examiner-specific positions.
SEUDIEU SEUDIEU, CARINE PATRICIA is the busiest examiner, with 1 pending action. No listed examiner carries a larger concentration, so docket control and matter-level review are important for maintaining consistent treatment across the portfolio.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (11%) |
| Double-patenting only | 2 (22%) |
| Double-patenting + other | 2 (22%) |
| Multi-statute (no §101) | 2 (22%) |
| No statute on record | 2 (22%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEUDIEU SEUDIEU, CARINE PATRICIA | 1 | — | — |
| BRAM, STANLEY | 1 | 0.0% | +0.0% |
| TRAN, ERIC | 1 | 69.8% | +19.4% |
| SAEED, KAMAL A | 1 | 83.8% | +9.8% |
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| FETTEROLF, BRANDON J | 1 | 51.6% | +18.5% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17614826 | METHODS OF ALTERING CARDIAC REMODELING USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | NESTOR, DONNA MICHELLE | 74d overdue |
| 18868353 | COMPOUNDS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | SEUDIEU SEUDIEU, CARINE PATRICIA | — |
| 18783819 | METHODS OF SYNTHESIZING 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL] PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE | BRAM, STANLEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17359714 | MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE | GONZALEZ, LUISALBERTO | 128d overdue |
| 17614826 | METHODS OF ALTERING CARDIAC REMODELING USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | NESTOR, DONNA MICHELLE | 74d overdue |
| 17922890 | DOSING METHODS FOR TREATMENT OF CARDIOVASCULAR CONDITIONS | FETTEROLF, BRANDON J | 53d overdue |
| 18780727 | METHODS OF TREATING HEART FAILURE WITH HIBERNATING MYOCARDIUM USING MODIFIED FORMS OF TRIMETAZIDINE | TRAN, ERIC | — |
| 16365074 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | NEAGU, IRINA | — |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| 1691 | 2 |
| 1629 | 2 |
| 1627 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18868353 | COMPOUNDS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | SEUDIEU SEUDIEU, CARINE PATRICIA | 1626 | §103§112Other | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18783819 | METHODS OF SYNTHESIZING 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL] PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE | BRAM, STANLEY | 1691 | §102§103§112DP | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18780727 | METHODS OF TREATING HEART FAILURE WITH HIBERNATING MYOCARDIUM USING MODIFIED FORMS OF TRIMETAZIDINE | TRAN, ERIC | 1629 | Other | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18703512 | METHODS FOR TREATING CARDIOVASCULAR CONDITIONS AND METHODS OF INCREASING THE EFFICIENCY OF CARDIAC METABOLISM | SAEED, KAMAL A | — | Other | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18624508 | METHODS OF TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION USING MODIFIED FORMS OF TRIMETAZIDINE | SHIAO, REI TSANG | 1691 | DP | Non-Final OA | — | Pending | Apr 02, 2024 |
| 17922890 | DOSING METHODS FOR TREATMENT OF CARDIOVASCULAR CONDITIONS | FETTEROLF, BRANDON J | 1626 | DP | Non-Final OA | 53d overdue | Pending | Nov 02, 2022 |
| 17614826 | METHODS OF ALTERING CARDIAC REMODELING USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | NESTOR, DONNA MICHELLE | 1627 | §103§112 | Final Rejection | 74d overdue | Pending | Nov 29, 2021 |
| 17359714 | MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE | GONZALEZ, LUISALBERTO | 1624 | §103DP | Non-Final OA | 128d overdue | Pending | Jun 28, 2021 |
| 16365074 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | NEAGU, IRINA | 1629 | §103 | Final Rejection | — | Pending | Mar 26, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImbria Pharmaceuticals Inc. has 9 pending office actions as of October 2026, spread across 5 art units and 9 examiners.
Carine Patricia Seudieu Seudieu has the most, with 1 of Imbria Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
